Turing Pharma names chairman to replace Shkreli as CEO

Screenshot


Turing Pharma names chairman to replace Shkreli as CEO

(Reuters) - Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday. Shkreli was replaced by Turing Chairman Ron Tilles, who said in a statement that the company was committed to continuing to make its flagship drug, Daraprim, which is used to treat an infection called toxoplasmosis in AIDS patients. Shkreli has become a lightning rod for growing outrage over soaring prescription drug prices after the company acquired Daraprim and raised its price to $750 a tablet from $13.50.
Views: 133
Author: Regular Articles
Tell a friend
Average rating:
(0 votes)

Hezbollah buries militant Qantar, says Israel will be held accountable

Lebanon's Hezbollah group said on Monday that Israel would be held accountable for killing prominent militant Samir Qantar in an air strike in Syria, and accorded him an elaborate funeral of... Read More

Russia says black box from warplane downed by Turkey unreadable

Investigators in Moscow said on Monday they were unable to retrieve information from the damaged black box of a Russian warplane shot down by Turkey last month, data the Kremlin hoped would support... Read More

Exclusive: U.S. glossed over Oman's human rights record during Iran talks

By Jason Szep, Matt Spetalnick and Yara Bayoumy WASHINGTON/MUSCAT (Reuters) - As the United States negotiated this year’s nuclear pact with Iran, the State Department quietly agreed to spare the... Read More